Menzies C B, Gunar M, Thomas D G, Behan P O
Clin Neurol Neurosurg. 1980;82(3):157-68. doi: 10.1016/0303-8467(80)90033-5.
Cell-mediated immunity was evaluated in 28 patients with malignant glioma, using in vivo and in vitro tests of lymphocyte function. The results were compared to those found in patients with carcinomatosis (11 subjects), benign brain tumours (9), other neurological disorders (20) and normal, healthy controls (21). Significant impairments of delayed hypersensitivity responses to common antigens was found in patients with malignant glioma and in those with generalised malignancy. A less significant depression of lymphocyte responses was also detected in patients with meningioma. The impairment in cell-mediated immunity was shown not be due to a serum blocking factor. Our data indicate that there is defective T cell function in patients with glioma, similar to that reported in cases with malignancies outside the central nervous system. This impaired immunity may have clinical significance.
采用淋巴细胞功能的体内和体外试验,对28例恶性胶质瘤患者的细胞介导免疫进行了评估。将结果与癌病患者(11例)、良性脑肿瘤患者(9例)、其他神经系统疾病患者(20例)以及正常健康对照者(21例)的结果进行了比较。在恶性胶质瘤患者和全身恶性肿瘤患者中发现对常见抗原的迟发型超敏反应有显著损害。在脑膜瘤患者中也检测到淋巴细胞反应有较轻微的抑制。细胞介导免疫的损害并非由血清阻断因子所致。我们的数据表明,胶质瘤患者存在T细胞功能缺陷,这与中枢神经系统以外的恶性肿瘤病例报道相似。这种免疫受损可能具有临床意义。